DAVID G. KING, MD
Urology at I St, Benicia, CA

7947465, May 24, 2011

Aug 7, 2008

12/187661

William F. Link - El Cerrito CA, US
Renato B. del Rosario - Benicia CA, US
Randy V. Sweet - Pinole CA, US
David L. King - Benicia CA, US

Bio-Rad Laboratories, Inc. - Hercules CA

G01N 33/00

435 793, 435 71, 4352872, 436513, 436517, 436518, 436523, 436526, 436538, 436540, 436 10, 436 18, 436172, 436175, 422 73, 422 8208, 422 8209, 424 92

Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles.

8137987, Mar 20, 2012

Apr 13, 2011

13/086229

William F. Link - El Cerrito CA, US
Renato B. del Rosario - Benicia CA, US
Randy V. Sweet - Pinole CA, US
David L. King - Benicia CA, US

Bio-Rad Laboratories, Inc. - Hercules CA

G01N 33/52, G01N 33/543

436518, 422 73, 422430, 422 8208, 422 8209, 436513, 436517, 436523, 436526, 436538, 436540, 436 10, 436 18, 436172, 436175, 435 71, 435 793, 4352872, 424 92

Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles.

5416023, May 16, 1995

Jul 6, 1994

8/271390

Steven R. Binder - Berkeley CA
David L. King - Benicia CA

Bio-Rad Laboratories, Inc. - Hercules CA

G01N 3002

435288

Biological samples are analyzed for benzodiazepines in a single isocratic analysis using a chromatographic column system containing an immobilized enzyme reactor which cleaves glucuronic acid-conjugated benzodiazepines, an anion exchange column, a hydrophobic cation exchange column and a reverse-phase analytical column. Preferred methods of performing the analysis further involve the use of a hydrophobic cation exchange precolumn prior to the anion exchange column. The system readily lends itself to automation, automatic periodic sampling and benzodiazepine identification and quantification. The system is particularly well adapted to the determination and identification of benzodiazepines in urine samples.

5352585, Oct 4, 1994

Jun 29, 1993

8/084845

Steven R. Binder - Berkeley CA
David L. King - Benicia CA

Bio-Rad Laboratories, Inc. - Hercules CA

G01N 3002

435 18

Biological samples are analyzed for benzodiazepines in a single isocratic analysis using a chromatographic column system containing an immobilized enzyme reactor which cleaves glucuronic acid-conjugated benzodiazepines, an anion exchange column, a hydrophobic cation exchange column and a reverse-phase analytical column. Preferred methods of performing the analysis further involve the use of a hydrophobic cation exchange precolumn prior to the anion exchange column. The system readily lends itself to automation, automatic periodic sampling and benzodiazepine identification and quantification. The system is particularly well adapted to the determination and identification of benzodiazepines in urine samples.

2009005, Feb 26, 2009

Aug 20, 2007

11/841649

William F. Link - El Cerrito CA, US
Renato B. Del Rosario - Benicia CA, US
Randy V. Sweet - Pinole CA, US
David L. King - Benicia CA, US

G01N 33/542

436537

A method and kits for assaying a sample of a human or mammalian bodily fluid to simultaneously determine whether one or more of a plurality of drugs and/or metabolites thereof are present in said sample and optionally to perform a semi-quantitative assay for said drug or drugs, comprising: